LeonaBio, Inc. Common Stock LONA Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Research And Development Expense Excluding Stockbased Or Depreciation Expense by Product | |||
| Acquired In Process Research And Development | $68.09M— | $0— | |
| ATH-1105 | $3.42M-60.1% | $8.57M— | |
| Fosgonimeton ATH-1017 | $2.33M-94.4% | $41.51M-37.6% | |
| Personnel-Related Costs Excluding Stock-Based Compensation | $4.22M-65.6% | $12.29M-11.9% | |
| Preclinical Programs And Other Costs | $1.25M-72.0% | $4.47M-45.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LeonaBio, Inc. Common Stock break its business down?
- LeonaBio, Inc. Common Stock (LONA) reports research and development expense excluding stockbased or depreciation expense by product across 8 parts — Acquired In Process Research And Development, ATH-1020, ATH-1105, Fosgonimeton ATH-1017 and Lasofoxifene. Each is extracted from the segment footnotes and tracked over time.
- Where does LeonaBio, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LeonaBio, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.